Osteopontin as a marker of weight loss in lung cancer.
Although the role of osteopontin (OPN) in tumorigenesis and invasiveness is well-known, its role in systemic consequences of lung cancer has not been studied yet. The objective of the current study was to assess the value of osteopontin as a marker of weight loss in relation to systemic inflammation in non-small cell lung cancer (NSCLC) patients. A total of 63 male NSCLC patients (stage III and IV) and 25 age and sex-matched controls were included. The NSCLC patients were further divided into subgroups depending on whether they had > 5% weight loss in the last 6 months or not. Serum OPN and TNF-α concentrations were measured by ELISA using commercially available kits. Serum C-reactive protein (CRP) concentration was measured by the turbidimetric method. OPN (p = 0.001) and CRP (p < 0.001) concentrations were significantly higher in lung cancer patients compared to controls whereas TNF-α concentrations were similar in cancer and control groups (p = 0.063). There were 33 NSCLC patients (52.4%) with weight loss. Serum OPN concentration was found to be higher in this weight-losing group (p = 0.042). CRP concentration was also higher in the weight-losing group but the difference was not statistically significant (p = 0.246). TNF-α concentrations were similar in both subgroups (p = 0.094). In correlation tests, there was a positive correlation between OPN and CRP (r = 0.299, p = 0.044), but no correlation was detected between OPN and TNF-α (r = − 0.009, p = 0.930). A negative correlation was detected between OPN and BMI (r = − 0.246, p = 0.048). In addition to being an indicator of systemic inflammation in lung cancer patients, osteopontin may also be an indicator of weight loss.
Department of Chest Diseases, School of Medicine, Adnan Menderes University, Aydin, Turkey. fisunkaradag@yahoo.com
Fisun
F
Karadag
Sule T
ST
Gulen
Aslihan B
AB
Karul
Naciye
N
Kilicarslan
Emel
E
Ceylan
Nilgun K
NK
Kuman
Orhan
O
Cildag
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D015992:Body Mass Index; D002097:C-Reactive Protein / Q000032:analysis; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000150:complications; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007249:Inflammation / Q000097:blood* / Q000150:complications; D008175:Lung Neoplasms / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D053495:Osteopontin / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood; D014421:Turkey; D015431:Weight Loss
D014408:Biomarkers, Tumor; D014409:Tumor Necrosis Factor-alpha; D053495:Osteopontin; D002097:C-Reactive Protein